Nirmatrelvir-ritonavir and simvastatine

被引：0
|
作者：
Legeay, Samuel [1 ]
Faure, Sebastien [1 ]
机构：
[1] Univ Angers, Fac Sante, Dept Pharm, 16 Blvd Daviers, F-49045 Angers, France
来源：
ACTUALITES PHARMACEUTIQUES | 2023年 / 62卷 / 630期
关键词：
CYP3A4; inhibition; nirmatrelvir-ritonavir; therapeutic regimen; simvastatin;
D O I：
10.1016/j.actpha.2023.09.004
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The combination of nirmatrelvir and ritonavir is indicated for the treatment of Covid-19 in adult patients at increased risk of progression to a severe form. Due to ritonavir's potent inhibition of cytochrome P450 3A4, it is contra indicated with simvastatin. In the event of co-prescription, the dispensing pharmacist should ask the patient to stop taking simvastatin for the duration of the antiretroviral treatment, and ensure that the patient complies with the new treatment regimen. (c) 2023 Elsevier Masson SAS. All rights reserved
引用
收藏
页码：17 / 19
页数：3
相关论文
共 50 条
  • [1] Nirmatrelvir-ritonavir for COVID-19
    McDonald, Emily G.
    Lee, Todd C.
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2022, 194 (06) : E218 - E218
  • [2] Impact of Nirmatrelvir-Ritonavir on Tacrolimus Concentrations
    Fredrick, S.
    Wise, B.
    Bowman, L.
    DeWolfe, D.
    Taylor, J.
    Melaragno, J.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 : 787 - 788
  • [3] Nirmatrelvir-ritonavir might only be effective in elderly patients
    Wang, Yu
    Chen, Xubo
    Liu, Xinbing
    Zhao, Danyang
    Feng, Liuliu
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (01)
  • [4] Nirmatrelvir-ritonavir (Paxlovid®), a treatment for Covid-19
    Buxeraud, Jacques
    Faure, Sebastien
    Fougere, Edouard
    [J]. ACTUALITES PHARMACEUTIQUES, 2020, 61 (617): : 10 - 12
  • [5] Nirmatrelvir-ritonavir for nonhospitalized patients with COVID-19
    LeBras, Marlys
    Crawley, Alex
    Legge, Marc
    Takaya, Satchan
    Lee, Stephen
    Regier, Loren
    [J]. CANADIAN FAMILY PHYSICIAN, 2023, 69 (08) : 546 - 549
  • [6] Benefits of nirmatrelvir-ritonavir remain unproven for some populations
    McDonald, Emily G.
    Lee, Todd
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2022, 194 (29) : E1041 - E1041
  • [7] Tacrolimus Level Increase During Nirmatrelvir-Ritonavir Treatment
    Gong, Yinhua
    Li, Yue
    Xue, Ling
    Gao, Jie
    [J]. AMERICAN JOURNAL OF THERAPEUTICS, 2024, 31 (04) : e458 - e461
  • [8] Real-world use of nirmatrelvir-ritonavir: who benefits?
    Molina, Kyle C.
    Ginde, Adit A.
    [J]. LANCET INFECTIOUS DISEASES, 2023, 23 (07): : 765 - 767
  • [9] Nirmatrelvir-Ritonavir and Viral Load Rebound in Covid-19
    Anderson, Annaliesa S.
    Caubel, Patrick
    Rusnak, James M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (11): : 1047 - 1049
  • [10] Rebound of COVID-19 With Nirmatrelvir-Ritonavir Antiviral Therapy
    Cohen, Myron S.
    Brown, Elizabeth R.
    [J]. ANNALS OF INTERNAL MEDICINE, 2023, 176 (12) : 1672 - 1673
12345